BioDelivery plunges on failed diabetic neuropathy gel study
This article was originally published in Scrip
Executive Summary
Shares of BioDelivery Sciences plunged 33% on 30 March after the firm said a Phase III trial revealed that its painful diabetic neuropathy topical gel Clonidine was no better than placebo – results that caught the company off guard.